key: cord-0826453-a8xhfxvb
authors: Dorri, Mahya; Bazargany, Mohamad Hossein Mozafari; Khodaparast, Zeinab; Bahrami, Soroush; Alan, Mahnaz Seifi; Rahimi, Fariba; Kamipoor, Zeinab; Niksima, Mohammad Mahdi; Dehghan, Hanieh; Rastad, Hadith
title: Psychological Problems and Reduced Health-Related Quality of Life in the COVID-19 Survivors
date: 2021-10-07
journal: J Affect Disord Rep
DOI: 10.1016/j.jadr.2021.100248
sha: d305c8f564239705016e63c0f77201276097ae63
doc_id: 826453
cord_uid: a8xhfxvb

BACKGROUND: COVID-19 survivors are predicted to experience the long-term consequences, including pulmonary, neurologic, cardiovascular, and mental health sequelae. This systematic review and meta-analysis was performed on studies assessing the health-related quality of life (HRQoL) and psychiatric problems in COVID-19 survivors. METHODS: A systematic search was performed on PubMed, Embase, and Google scholar databases using key terms COVID-19, PTSD, depression, anxiety, HRQoL, survivors. Pooled estimates were calculated using the random-effects models. RESULTS: A total of 21 eligible articles were included included. The pooled prevalence of PTSD, depression, and anxiety among COVID‐19 survivors were 18% (95% CI: 13 to 23%, I(2)=88.23%), 12% (8 to 17%, I(2)=91.84%), and 17% (12 to 22%, I(2)=97.07%), respectively. COVID‐19 survivors compared to pre-COVID-19 time and controls showed reduced HRQoL and a lower score in Social Functioning (SF) and Role Physical (RP), and Role Emotional (RE) health. Females compared to males had a higher risk of experiencing mental health problems. Also, patients with severe disease had a higher prevalence of depression and anxiety, but not PTSD. LIMITATIONS: Regarding HRQoL, we were not able to perform a subgroup analysis due to a lack of data. Also, the included studies mainly used a self-rating scale to detect psychological problems in their study population. CONCLUSION: A significant number of patients who survived from COVID-19 might suffer from PTSD, depression, and anxiety beyond one month. Our systematic review also found evidence of reduced HQOL and limited social role in these survivors

SARS-CoV-2 is the third member of the coronavirus family, with less fatality but more transmissibility and infectivity than other family members. [1] It has infected over 106 million people worldwide, of whom over 59 million people have survived as of 7 February 2021. [2] Given the prior experience with coronavirus outbreaks, it has been supposed that COVID-19 survivors may not fully recover, and some of them are supposed to be affected by the long term sequels [3] , psychological problems, such as post-traumatic stress disorder (PTSD), depression, and anxiety, and reduced quality of life are probably among the key health issues facing survivors. [3] [4] [5] A high prevalence of these psychological sequelae was reported in survivors of other coronavirus infections, Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) [6] . Also, post-illness stage patients infected by other epidemic diseases, such as MERS and H1N1 Influenza have frequently experienced the short-term or longterm quality of life problems [4] . COVID-19 is likely to have the similar mental health sequelae in a group of survivors [7] .

Currently, the exact mechanistic pathways underlying psychological and psychiatric symptoms after COVID-19 are unclear. Infection-triggered perturbation of the immune system is suggested to play a main pathophysiological role for the post-COVID-19 mental health issues. [8] In addition to the immunological mechanisms, treatment for COVID-19, the psychological stress of enduring a potentially fatal disease, stigma, and social isolation experienced by patients during the COVID-19 may have an adverse effect on the mental health and contribute to mood disorders, psychosis, and anxiety disorders. [9] Furthermore, COVID-19 mental health sequelae might be induced directly through the viral infection of the central nervous system (CNS). [10] Follow-up studies have measured the psychological distress and the health-related quality-oflife (HRQoL) among COVID-19 survivors to identify the clinical needs of COVID-19 survivors to rehabilitation and mental health services. However , to our best knowledge, no systematic reviews have been conducted in this regard.

Therefore, this review aimed to summarize the available evidence on the reduced HRQoL and the prevalence of psychiatric problems, including PTSD, depression and anxiety, and HRQoL among COVID-19 survivors.

This systematic review was conducted in accordance with the recommendations outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [11] . As no human subjects were involved, no ethical approval was required for conducting this study. The study protocol was registered on PROSPERO (ID:

All eligible studies assessing post-trauma stress disorder (PTSD), anxiety, depression, or Healthrelated quality of life (HRQoL) in COVID-19 patients during the post-acute phase were included in this study.

A systematic search of three electronic databases such as , PubMed, Embase, and Google Scholar, was performed on 12 November 2020 and updated on 16 January 2021.

While tailoring for each database, the following key terms were combined by Boolean "OR" in each domain, and these domains were combined by "AND":

The population studied: "survivors" OR "recovered patients" OR "discharged patients."

Exposure: "COVID-19", "sars-COV-2", "novel corona", "2019-nCOV" Outcome: PTSD, anxiety, depression, or HQOL The reference list of each relevant article was manually checked to retrieve potentially eligible items which were not captured by electronic database searches.

Two independent researchers [HM & MD] initially screened articles by titles and abstracts, followed by full texts to identify studies that met the eligible criteria. Disagreements were resolved by consulting a third researcher (HR or MS).

We included the observational studies that fulfilled all five following inclusion criteria:

Having a case series or cohort design Written in English and published in a peer-review journal Including adult COVID-19 out/inpatients who were discharged from the hospital or recovered Evaluating at least one of the following outcomes: PTSD, anxiety, depression, or HQOL A sample size of ≥30 participants

We assessed four outcomes, such as PTSD, depression, anxiety, and HRQoL, measured using clinical diagnosis, standardized and validated scales, or self-report.

Three independent researchers [FR, ZK & HD] extracted the following data from the eligible studies and recorded them in a 'Data Extraction Form' generated using Microsoft Excel:

First author's name, country, study design, sample size, age, sex ratio, response rates, presence of comorbidities, follow-up duration (from diagnosis or discharge), assessed outcomes, assessment tools, and main findings. Extracted data were organized and presented at the systematic review tables.

Two members of the research team [ZKh &MMN] independently evaluated the quality of the included articles using the Newcastle -Ottawa scale (NOS) for the cohort studies, [12] and any disagreement was resolved through involving a third researcher [HR, MS, MD, or MHM ].

This appraisal tool contained nine items, and their total score ranged from 0 to 9; based on the total score, the studies fell into one of the following quality-categorizes: Poor (0-3 scores), Fair (4-6 scores), or Good (7-9 scores). (Table 1 )

We used a random-effects model to estimate pooled means or proportions of relevant COVID-19 outcomes, including PTSD, anxiety, depression, and HRQoL,

We assessed for heterogeneity using the I2-statistic. Overall, I 2 ≥ 50% was considered to have significant heterogeneity. The following subgroup analyses were performed to determine the source of the observed heterogeneity: gender, follow-up duration, study design, clinical severity, and hospitalization status. We employed Egger's test to assess the presence of publication bias.

A univariate meta-regression analysis was performed to explore the impact of some covariates on each psychological outcome's pooled prevalence. Our covariates of interest included mean/median age, sex ratio, study design, sample size, and the mean/median follow-up duration of the prevalence of psychological outcomes. In the meta-analysis performed on the prevalence of psychological consequences, subgroup analyses were performed to explore the possible heterogeneity sources based on the categories of the following variables: sex, disease severity, hospitalization status, follow-up duration, assessment tool, and study design.

All statistical analyses were conducted using the STATA's METAN package (version 16).

A total of 1,320 items were identified by the original search from three databases, of which 350 were duplicates and a further 949 were excluded after screening titles/abstracts (n=830) or full texts (n=119). The reasons for the exclusion of the articles are provided in Table 2 .

Hence, we included 21 articles which met the study eligibility criteria, including 8 prospective and 13 retrospective cohort studies. Figure1 shows the selection process in detail.

Overall, the included studies addressed psychological problems (n=11), [9, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] HRQoL (n=7), [23] [24] [25] [26] [27] [28] [29] or both of them (n=3) as COVID-19 sequelae [30] [31] [32] in survivors. Table 3 presents the detailed characteristics of all the eligible studies.

These studies all focused on the general population and involved a total of 49,650 COVID-19 survivors aged 18 years or older from 10 countries around the world. In detail, the sample size varied from 58 in the Raman et al.'s study [32] to 44,779 to the Taquet et al.'s study [18] . Studies were carried out in China (n=6), Italy (n=4), United Kingdom (UK; N=3), United States (USA, N=2), Canada (N= 1), Netherlands (N=1), France (N=1), Korea (N=1), Turkey (N=1), and Bangladesh (N=1). Three stdies failed to provide data on the eligible participants' response rate [13, 28, 32] , which ranged from 24% to 98% across remained studies.

The mean/median age of COVID-19 patients mainly fell in the fifth to seventh decades, with a male predominance in 16 out of 21 studies. Median/mean time from diagnosis/discharge to the follow-up assessment varied from 23 days to 111 days across the studies, , and nearly half of them were greater than 31 days.

In 16 studies, inpatients constituted 100% of the study participants, and in remaining studies but one, the proportion of outpatients ranged from 16% to 40%. The exception was the large study conducted by Taquet et al. [18] that included both inpatients and outpatients but failed to provide more information about their ratio. Besides, ten studies provided data on the severity of disease at the acute phase experienced by the participants. In these studies, patients with a severe form of the disease constituted at least 9.4% to a maximum of 54% of the study population.

All studies had a quality score greater than four and fell in the good (n= 6) or fair (n=15) category.

Overall, of 14 studies investigating the psychiatric sequelae of COVID-19 as an outcome, only Y Liu et al. [20] and Taquet et al. [18] examined the presence of an actual disorder based on clinical diagnoses rather than self-reported symptoms. Nine out of twelve remaining studies used the validated instruments, of which seven studies utilized corresponding cut-off values for the evaluation. Table 4 summarizes results of studies investigating psychological outcomes at the total study population. Table 5 and Figure 2 also present meta-analysis results for each psychological outcome, overall and by subgroups.

A total of eight studies reported the prevalence of PTSD among COVID-19 survivors. This indicator of psychological distress was measured using validated scales (n=5), including PTSD Checklist for DSM-5 (PCL -5) and/or Impact of Event Scale-Revised (IES-R), Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) criteria (n=1), or a single question on "having PTSD" (yes/no, n=1) ( Table 4) Mazza et al. [17] and Borst et al. [9] measured the presence of PTSD using the two scales, namely PCL-5 and IES-R, and utilized a cut-point value of 33 for both of them. As the optimal cut-off score for IES-R is 46 scores [33] , the results of the PCL-5 were included in the metaanalysis to reduce the overestimation of the overall prevalence.

Overall, the prevalence of PTSD ranged from 7.3% in the Netherlands [9] to 31% in the UK [31] .

The pooled prevalence of PTSD was 18% (ranging from 13 to 23%) with a substantial heterogeneity (I 2 = 88.23%, P-value < 0.001). The prevalence of PTSD was higher among female patients than males ((23% (95% confidence interval (CI): 10 to 35%) vs. 12% (7 to 16%) respectively, P-value < 0.001) and among outpatients (28% (22 to 34%) than inpatients (22% (17 to 28%). Based on the pooled results from three studies, in the subgroup analysis by the disease severity, the similar prevalence of PTSD was observed in patients with mild (15% (0 to 30%)), moderate (14% (6 to 22%), and severe disease (13% (6 to 21%)). (P-value = 0.99) Besides, a higher pooled prevalence of PTSD was obtained from the retrospective cohort studies compared to prospective ones (21% (15 to 27%) vs. 11% (8 to 14%) respectively, P-value < 0.001).

However, in the subgroup analysis by the follow-up duration, approximately the similar prevalence was obtained from the studies with a mean/median follow-up duration ≤ 31 days and those with a longer follow-up time (P-value = 0.58) ( Table 5) . Mazza et al. [17] utilized two scales, BDI-13 (Cut point: ≥ 9) and ZSDS (≥ 50). As cut point value 50 for ZSDS involved patients with mild depression, [34] the results of the BDI-13 scale were included in the meta-analysis to prevent the potential overestimation of the pooled estimate.

Among eligible studies, the prevalence of depression ranged from 4.3% (self-reported) in the Xiong et al.'s study [19] to 30.7% (ZSDS ≥ 50) in Mazza et al.'s study [17] ( Table 4 ).

The overall pooled prevalence of depression was 12% (95% CI: 8 to 17%) with substantial heterogeneity 91.84%, P-value <0.001). The prevalence of depression was higher among female patients than males (19% (15 to 22%) vs. 12% (9 to 15%) respectively, (P value < 0.001)) and in patients with severe disease (22 % (16 to 28%)) than those with moderate (15% (11 to 18%)) and mild forms (13% (8 to 18%)), (P value = 0.04). Furthermore, the pooled prevalence was similar between studies with mean/median follow-up duration ≤ 31 days and those with longer followup time (>=31) (16% (13 to 18%) vs. (15% (2 to 28%) respectively, P value= 0.86) and between retrospective (12% (5 to 18%)) and prospective (12% (9 to 15%)) cohort studies (P value =0.94). (Table 5 )

Overall, nine studies evaluated anxiety as an indicator for psychological sequelae of COVID-19 among survivors. Studies used different methods to measure anxiety, including clinical diagnosis (DSM-IV or ICD-10) (n=2), a single question on "having anxiety" (yes-no, n=1) or one of the following validated scales (n=6): The Generalized Anxiety Disorder-7 (GAD-7), The State-Trait Anxiety Inventory (STAI), TEMPS-A, OR HADS. Eight out of nine studies reported the prevalence of anxiety, its prevalence ranged from 4.8% in Y Liu et al.'s study [20] (China) to 42% in Maaza et al.'s study [17] (Italy). (Table 4) Overall, the pooled prevalence of anxiety was 17% (95% CI: 12 to 22%) with a significant heterogeneity (I 2 =97.07%, P-value < 0.001).

The pooled prevalence of anxiety was higher among females compared to males (19% (16 to 22%) vs. 8% (6 to 11%) respectively , (P-value < 0.001)) and in patients with a severe form of the disease (16% (10 to 21%)) compared to those with moderated (8% (6 to 11%)) and mild forms (8% (4 to 12%)), (P-value = 0.04). In the subgroup analysis by the assessment tools, the highest pooled prevalence was obtained from studies that used the STAI-Y scale (42% (38 to 46%)).However, in the subgroup analysis by follow-up duration and study design, the pooled prevalence was higher in studies with mean/median follow-up duration ≤ 31 days than those with longer follow-up time (>=31) (24 (16 to 32) vs. 13% (9 to 17%)respectively, P-value = 0.03 was statistically significant in prospective studies than retrospective studies (27% (10 to 45%) vs 14% (9 to 18%) respectively, P-value = 0.14). (Table 5) Besides, a total of three studies evaluated the presence of -anxiety or depression‖ as a single outcome based on the patients self-reporting of having at least one of them; the proportion of patients who reported having anxiety/depression, in order by frequency, was 35% in Halpin et al.'s study [31] (UK), 22% in Akter et al.'s study [13] (Bangladesh), and 14% in the Wong et al. study [21] (Canada). (Table 4 ) A meta-analysis of these studies yielded an overall pooled prevalence equaling 23% (14 to 32%).

-Risk factors of psychological impacts: a qualitative assessment Risk factors for a more significant psychological impact of COVID-19 among its survivors were substantially similar for indicators of PTSD, anxiety, and depression. Common associated factors were mainly being female and the severity of the disease. Other significant risk factors reported with less frequency were being outpatient, having comorbidity, previous psychological distress, length of stay (LOS) at the hospital, having lower income, lower level of education, and perceived discrimination. However, not all studies detected these significant associations.

Besides, studies consistently reported no significant association between the presence of these COVID-19 psychological sequelae with the survivors' age and marital status. (Table 4 )

We detected no significant correlations between the pooled prevalence of each psychological outcome and study-level factors, including mean/median age, sex ratio, study design, sample sizes, and mean/median follow-up duration (all P > 0.05) in the meta-regression analyses. Also, according to Egger's regression test, there was no evidence of publication bias (for all psychological outcomes, P >0.05).

Ten studies evaluated HRQoL in COVID-19 survivors. In terms of the assessment tool, all studies but one used a validated scale, including short-form 36 health survey (SF-36; N=4), [23, 25, 27, 32] St George's Respiratory Questionnaire (SGRQ; n=1), [28] World Health Organization Quality of Life (WHOQOL)-BREF (n=1), [30] or 5-level EuroQol five-dimension (EQ-5D-5L; n=3), [24, 26, 31] . Table 6) Four out of ten studies reported a mean (SD) of SF-36 domains [ Figure 2 ], conducted in two countries, the UK (n=2) [23, 32] and China (n=2) [25, 27] . In contrast to other studies, the study of Gue et al. [27] [25, 27] (Table 6) The meta-analysis was conducted on these four studies, based on the pooled estimations of Other studies that utilized other tools also reported that a HRQoL was reduced in survivors at follow-up time compared to pre-COVID-19 time or controls. Some studies found that the severity of disease and persistent symptoms of COVID-19 might be associated with reduced HRQoL among COVID-19 survivors. Other identified associated factors included female gender , age, and LOS (Table 6 ).

The main objectives of the current systematic review and meta-analysis were to: (1) assess the HRQoL status of COVID-19 survivors and (2) provide an overall estimate of the prevalence of PTSD, depression, and anxiety among them by combining the data of 21 observational studies with a total of 49,650 patients. Based on our findings, the overall prevalence of PTSD, depression, and anxiety among COVID-19 survivors were 18% (95 CI: 13 to 23%), 12% (8 to 17%), and 17% (12 to 22%), respectively. Our findings highlighted that COVID-19 survivors showed a reduction in HRQoL, measuring using different scales.

Our subgroup analysis revealed a higher prevalence of depression and anxiety, but not PTSD, in patients with severe disease compared to others. Also, all three mental health problems were more common in females than males. Based on our systematic review of the literature, other potential risk factors for the mental health sequelae of COVID-19 included being outpatient, having comorbidity, a history of psychological distress, hospital length of stay, a low level of education, income levels, and perceived discriminations.

Our meta-analysis showed that about one out of five to ten COVID-19 patients might suffer from psychological conditions, such as PTSD, depression, or anxiety during the post-acute phase of the disease or after recovery. In line with our findings, a recent meta-analysis revealed that PTSD (32·2% (95% Confidence Interval (CI): 23·7-42·0)), anxiety disorders (14·8% (95% CI: 11·1-19·4)), and depression (14·9% (95% CI: 12·1-18·2)) were prevalent among survivors of other coronaviruses at a mean follow up of 35 months [6] .

during the acute phase of the disease revealed that about half of them suffered from depression and/or anxiety, and one-third of them had sleep disturbances [35] . A higher prevalence of psychological outcomes detected by Deng et al. in comparison with our study can be justified by this methodological issue that they focused on patients during the acute phase of the disease.

The exact Mechanism underlying mental health sequelae of COVID-19 are unknown. Viral invasion of the CNS, [10] neural effects of the immune response, [8] and psychological stress of enduring a potentially fatal disease [9] are supposed to be the main potential mechanisms for COVID-19 mental health sequels. Also, as reported in previous studies on SARS survivors, people may avoid interacting with recovered patients for fear of infection [36] ; this perceived discrimination and feeling isolated could contribute to developing mental health problems in COVID-19 survivors [16] .

Some factors may put patients at a higher risk for the development of psychological and psychiatric symptoms after recovery of COVID-19. In this systematic review study, four out of six included studies reported that female gender was a significant risk factor for experiencing psychiatric sequelae of COVID-19 after hospital discharge. Some also found that the female gender is associated with the increased severity of PTSD symptoms. [20, 22] A previous longitudinal study on SARS survivors revealed that female gender and the presence of chronic comorbidities are the independent predictors of PTSD. [40] It is well known that females are more prone to emotional distress and traumatization subsequent to major stressors. They are more likely to suffer from depressive and anxiety disorders and have a higher risk for PTSD for traumatic events than males [41] .

Overall, females are also at higher risk of disorders of anxiety and depression [42] . This greater vulnerability may be explained by the immune-neuro-endocrine interactions and/or their different innate and adaptive immune system functioning. [43] Two out of five studies assessing the association between hospitalization status and psychological sequelae in COVID -19 survivors observed that outpatients are at a higher risk of developing PTSD and anxiety disorder [17, 30] , which may be explained by the lack of healthcare support for the non-hospitalized patients. However, others failed to detect any significant association [14, 20, 22] . These findings showed that the psychological sequelae not only suffered from serious illness, but also from factors, such as fear [44] and stigma [45] that may play a key role. Also, based on the available evidence, the pre-existing psychiatric history of subjects is a risk factor for the COVID-19 mental health sequelae; therefore, this factor is well known as a predictive factor for the occurrence of psychological problems later in life [46, 47] .

Given the population size of COVID-19 survivors, the prevalence of psychological problems could be fairly characterized as massive in a public health sense. According to the available evidence, stress-related disorders are associated with having suicidal ideation, suicide attempts, and suicide death. [37] Hence, it is suggested that COVID-19 survivors be regarded as a high-risk group for suicide. [38] Further, individuals with depression are at a higher risk of all-cause and cause-specific mortality [39] .

Also, as a large proportion of the study populations were patients with mild to moderate SARS-CoV-2 infection, our findings can be alerting as the presence of psychiatric sequelae which may be more easily discounted in this group of survivors.

Hence, COVID-19 survivors would need the long-term psychological interventions. It implicates the need to provide mental health care for millions of survivors globally with the depressive and related disorders. Specific strategies should be considered to enhance the mental health of COVID-19 survivors and reduce suicidality (i.e., suicidal ideation and suicide attempts) in this population [38] .

Most of the included studies in this review reported that survivors had a lower quality of life than controls or their status at pre-COVID-19. Our Meta-analysis revealed that three domains such as , SF, RP, and RE scores significantly lower in COVID-19 survivors than controls. In line with our findings, Ahmed et al. found that HQOL was significantly reduced in survivors of other coronaviruses compared to normative values for healthy and people with chronic diseases [4] . days after discharge and found that fatigue, pain, and/or dyspnea were present in over half of them [29] . They also found that persistent symptoms are inversely associated with odds of a socially active role. Zhou et al. found the significant negative correlations between SGRQ scores and lung ventilator function variables in COVID-19 survivors [28] .

As the first main limitation, we observed a large between-study heterogeneity for all psychological outcomes that its source was not identified by subgroup analysis and meta-regression analysis. None of the study-level factors, such as sample size and follow-up duration, could explain the large heterogeneity observed between the studies. However, a random-effects model was performed to address the observed heterogeneity.

Second, our results should be interpreted with caution because the included studies mainly used self-rating scales to assess the prevalence of psychological problems that mostly have lower sensitivity and specificity than observer-rated scales [48] and structured clinical interviews [49] .

Finally, regarding the HRQOL outcome, we could not perform a subgroup analysis to compare subgroups, such as male and female patients with different severity of the disease due to lack of subgroup data.

However, our systematic review and meta-analysis highlighted the burden of psychological issues in COVID-19 survivors. Our findings inform public health to plan the appropriate interventions and prepare mental health and social care services for the utilization of healthcare services after COVID-19.

There is a need for future comparative studies to identify the effective early interventions that may decrease psychiatric morbidity in COVID-19 survivors.

Our findings suggest that a group of COVID-19 survivors would have reduced HQOL and limited social role beyond one month. Psychological distress, including PTSD, depression, and anxiety, should be expected in a large number of them.

Funding: This study received no specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

HR had the idea for designing the study, performed all statistical analyses, and critically Not having a case series or cohort design 19 Sample size less than 30 12 Age of participants 9 Total 1,299 

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update. Cureus

The Novel Insight of SARS-CoV-2 Molecular Biology and Pathogenesis and Therapeutic Options

Long-term sequelae following previous coronavirus epidemics

Long-term clinical outcomes in survivors of coronavirus outbreaks after hospitalisation or ICU admission: a systematic review and meta-analysis of follow-up studies. medrxiv

COVID-19 interstitial pneumonia: monitoring the clinical course in survivors. The Lancet Respiratory Medicine

Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the COVID-19 pandemic. The Lancet Psychiatry

Are the COVID-19 survivors future patients of psychiatrists and psychologists A rapid literature review

Correlation between immune response and self-reported depression during convalescence from COVID-19. Brain, behavior, and immunity

Comprehensive health assessment three months after recovery from acute COVID-19

Multidisciplinary research priorities for the COVID-19 pandemic: a call for action for mental health science. The Lancet Psychiatry

Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias

Newcastle-Ottawa quality assessment scale cohort studies

Clinical characteristics and short term outcomes after recovery from COVID-19 in patients with and without diabetes in Bangladesh

Incidence of post-traumatic stress disorder after coronavirus disease. in Healthcare

Psychological Distress After Covid-19 Recovery: Reciprocal Effects With Temperament and Emotional Dysregulation. An Exploratory Study of Patients Over 60 Years of Age Assessed in a Post-acute Care Service. Frontiers in psychiatry

Risk factors associated with mental illness in hospital discharged patients infected with COVID-19 in Wuhan, China. Psychiatry research

anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain, behavior, and immunity

Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. The Lancet Psychiatry

Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study

Mental Disorders, Fatigue, Perceived Event Impact, and Coping in Post-Illness Patients with COVID-19 within 1 Month after Discharge: A Case-Controlled Study

Patient-reported outcome measures after COVID-19: a prospective cohort study

Psychiatric morbidity and protracted symptoms after COVID-19

Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort

Persistent symptoms in patients after acute COVID-19

Predictors of health-related quality of life and influencing factors for COVID-19 patients, a follow-up at one month. Frontiers in Psychiatry

Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19

Correlation study of short-term mental health in patients discharged after coronavirus disease 2019 (Covid-19) infection without comorbidities: A prospective study

Multifaceted Examination and Assessment of COVID-19 Convalescent Patients in Wuhan, China: A Follow-Up Study of Survivors Three Months after Discharge

Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection

Residual clinical damage after COVID-19: A retrospective and prospective observational cohort study. Plos one

Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: A cross-sectional evaluation

Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. EClinicalMedicine

Exploring optimum cut-off scores to screen for probable post-traumatic stress disorder within a sample of UK treatment-seeking veterans

Measures of depression and depressive symptoms: beck depression inventory-II (BDI-II), Center for Epidemiologic Studies Depression Scale (CES-D), geriatric depression scale (GDS), hospital anxiety and depression scale (HADS), and patient health Questionnaire-9

The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis

Fear and stigma: the epidemic within the SARS outbreak. Emerging infectious diseases

Resilience as a focus of suicide research and prevention

Are COVID-19 survivors at increased risk for suicide? Acta neuropsychiatrica

Is excess mortality in depression generic or specific? A comprehensive meta-analysis of community and patient studies

Risk factors for chronic post-traumatic stress disorder (PTSD) in SARS survivors. General hospital psychiatry

Post-traumatic stress disorder in adults: impact, comorbidity, risk factors, and treatment. The Canadian Journal of Psychiatry

Sex differences in anxiety and depression clinical perspectives. Frontiers in neuroendocrinology

Study finds COVID-19 survivors exhibit MH signs one month after treatment. Mental Health Weekly, 2020

Neuromuscular disorders in severe acute respiratory syndrome

Mental morbidities and chronic fatigue in severe acute respiratory syndrome survivors: long-term follow-up. Archives of internal medicine

Psychiatric history and subthreshold symptoms as predictors of the occurrence of depressive or anxiety disorder within 2 years

Predictors of post-traumatic stress disorder and symptoms in adults: a meta-analysis

Rating depressed patients: observer-vs self-assessment

comparison of self-report and structured clinical interview in the identification of depression